NNB Nutrition (https://nnbnutrition.com/), a cutting-edge branded ingredient supplier and creator, delivers new and novel ingredients with an elite global team of scientists, recently announced that they have filed a PCT patent (PCT/CN2021/101541)on the use of MitoPrime®(L-Ergothioneine) to alleviate and prevent age-related macular degeneration(AMD). In this patent’s research, NNB discovered that MitoPrime can actively prevent age-associated visual degeneration in the mammal.
Age-related macular degeneration consists of phenomenon including eyestrain, blurred vision, dry eyes, eye fatigue, and even ultimately blindness, etc. AMD is a major cause of central visual loss in the developed world affecting 10% of people older than 65 years and more than 25% of people older than 75 years. In the US alone, 2 million individuals have advanced AMD and over 8 million individuals have an intermediate form of this age-related degeneration. These numbers are expected to rise by 50% in 2022. In Saudi Arabia, AMD represents 3.3% of the major causes of blindness in individuals older than 50 years. As human society ages globally, especially over the age of 40, the senescence and degeneration of ocular organ function becoming increasingly common, which might bring inconvenience to individuals and increase the social burden. The elderly with senescence and degeneration of ocular organ function can be called age-related visual degeneration. The age-related visual degeneration might damage the outer retina, such as retinal pigment epithelium (RPE, an important role in absorbing light), Bruch’s membrane (BM), and the underlying choroid (choriocapillaris), and photoreceptors. Therefore, focusing on the eye health of the elderly is now becoming a new trend in the current health care product market.
Because of this, NNB’s discovered surely added MitoPrime more market value. Not only that, but NNB's patented experiment was also carefully designed: NNB used zebrafish as the experimental object in the patent experiment, and the main reason is that the zebrafish fundus model is recognized in the academic circle as the most similar model to the human eye. Meanwhile, the visual fatigue of zebrafish is also very similar to that of humans. Therefore, as long as the effectiveness of the substance in the eyes of zebrafish is proved, it can be concluded that it will have the same effectiveness in the human body. NNB is also the first company to use zebrafish to study the effect of EGT on eye health, which is also an innovative experiment of great significance in the dietary supplement industry.
In the nnb's experimental report, the researchers used inducing factors to first make zebrafish show symptoms of age-related macular degeneration, and then these zebrafish were grouped and placed in water containing different substances. The researchers found that zebrafish placed in MitoPrime-containing water had a significant reduction in the degree of macular degeneration, and also with the improvement in the health of the eyes; the effect was even comparable to that of zebrafish placed in a liquid drug specifically designed to alleviate macular degeneration.
MitoPrime®, NNB's pure Ergothioneine, is NNB Biotech’s bio-perfected form of the histone derivative L-ergothioneine now is backed by over 15 studies including clinical trials, human cell & pharma-model C Elegans. MitoPrime® L-ergothioneine is a naturally water-soluble amino acid with a powerful energy-boosting antioxidant property, which benefits in longevity, antioxidant, DNA & genomic stability, immunity boost, anti-inflammation, and cellular & organ health, and can be formulated or work as the sole active ingredient. It is 100% natural, non-GMO, and contains no additives of any kind.
NNB believes that regulatory certification such as GRAS and FSSAI, as well as clinical trials and patents can add more value to the product itself, and also enable MitoPrime to be used more widely, such as in daily supplement, skin care, cosmetics, food, beverages etc. NNB is also looking forward to discussing with you the wider application scenarios of MitoPrime.